Management Team


President & CEO

Dr. Liu has 30 years of product, process development and manufacturing experience in biotech, pharmaceutical and specialty chemical industries. Prior to returning to Taiwan to start up EirGenix, Dr. Liu was the President and COO of AnGes Inc., a biotech enterprise in its late developmental stage.  

He joined AnGes in 2002 as a Vice President of Product Management. He also served as a Vice Chairman in the Supervisory Board of Avontec GmbH, a Munich based joint venture with AnGes, from 2004 to 2010. 

Before his tenure with AnGes, he had served various management and professional positions to lead product/process development at GenVec, Novartis, W.R.Grace & Co. and Halcon SD.  

Dr Liu holds a doctoral degree in Chemical Engineering & Applied Chemistry from Columbia University, and a BS degree in Chemical Engineering from National Taiwan University.


Managing Director of EirGenix Europe GmbH

Dr. Thomas Schulze`s scope of experience covers numerous areas in pharmaceutical R&D and biotechnology, including biological and small molecule drug discovery and development, molecular diagnostics and product authentication.

From 1990 – 1999, he worked in pharmaceutical drug discovery and development at Bayer AG and Bayer Yakuhin, Ltd. while heading a department in Japan and global drug discovery and genomics projects across several indication areas in Germany. During 1999 – 2012, he served in different executive management positions as COO, CEO and Interim-CEO at several industrial biotech companies, including November AG, Avontec GmbH, Formycon AG.

From 1984 – 1990, he worked at the Max Planck Institute for Molecular Genetics on the characterization of the HIV replication cycle in Berlin where he conducted his diploma and doctoral thesis. Dr. Schulze received his doctoral degree from the Free University Berlin/Dept. Biology in 1989.


Vice President, Chief Operating Officer (COO)

Dr Chih-Jung Chang is an Organic Chemist and has majored on the pharmaceutical field for nearly 20 years. He once worked as the director of TOT Oncology Business Unit at TTY Biopharm. During which, his main responsibilities included project management creating business and drug development strategies for licensing and collaboration in global NCE (Specialty)/Biologics (NBE/Biosimilars) projects. 

With both technical knowledge and business acumen, Dr. Chang has extensive experiences building up new biologics and specialty pipelines that fit the company’s development strategy. In addition, Dr Chang has extensive experiences managing international networking and relationships for value-added bridge between early and late stage drug development. In particular, Dr Chang has extensive experiences working with global CRO/CMO resources to fast track drug development. 

Before assuming the current position, Dr Chang was with TaiGen Biotechnology and was in charge of managing the company’s R&D projects and business development.


Vice President, Chief Technology Officer (CTO)

Dr. Yeh spent 24 years in bio-pharmaceutical and pharmaceutical industry in the US after obtaining his doctoral degree.  Prior to returning to Taiwan to join EirGenix, Dr. Yeh was Executive Director in Process Development, Amgen (2011-2019).  Prior to Amgen, Dr. Yeh held increased responsibility in managerial and technical leadership in Biogen Idec (2006-2011) and GlaxoSmithKline/SmithKline Beecham (1995-2006).  

During his tenure in the US, Dr. Yeh has engaged and involved with the development of a diverse set of therapeutic modalities (both biologics and synthetics) in molecular design, process and product development and manufacturing, including product life cycle management.  He has contributed to the successful launch of 17 commercial products and 45 IND/INDa filings. 

Dr. Yeh received his Ph.D. in Pharmaceutics and Pharmaceutical Chemistry under Professor Jindrich Henry Kopecek, and M.S. in Material Sciences and Engineering under Professor Joseph Andrade, both from The University of Utah. He received his B.S. degree in Chemical Engineering from Tamkang University in Taiwan.




Vice President, Quality System

VP. Teng, Chih-Den has more than 30-year working experience in the Pharmaceutical and Biotech industry. He has a Pharmacy degree from Kaohsiung Medical University and is the licensed Pharmacist in Taiwan.

Pharmacist Teng has profound and practical experiences in build-up pharmaceutical manufacturing sites and establishing GMP system, and also, he dedicates to train for TFDA and for pharmaceutical associations PITDC, TPDA, TPQRI on the topics of GMP inspection and GMP System.

During his professional career, he was the Vice President for 6 years, for 11 years as a Tech Director,  and for 17 years as a Plant Manager and Quality Manager. He also holds leadership and managerial skills in the pharmaceutical industry.




Vice President, Chief Financial Officer (CFO)

Ms. Yang has more than 20 years of experiences in FMCG (Fast Moving Customer Goods) and medical industries. Prior to joining EirGenix, she has been responsible for accounting, finance, HR, administration, and IT departments and also has vast experience in the management and operation of the medical provider channel. Ms. Yang was a General Manager of ERS, which is a JV company between Fresenius and Excelsior, overseeing the management and operations of 100+ kidney dialysis centers in Taiwan. Ms. Yang holds a Master of Science in Accounting from University of New Haven in Connecticut (U.S.).



Executive Director, Chief Manufacturing Officer

Dr. Shang-Chung Ju has been working in the biotechnology area since 1989 after he earned his Ph.D. degree from National Taiwan University.  His experience has been in the areas of bioprocess development, process transfer, and GMP manufacturing in biopharmaceutical pilot plant facility in DCB (Development Center for Biotechnology), Taiwan. 

As a project manager, he has more than 5 years’ experience in managing process development team and manufacturing team to achieve clients’ goals through the contract development and manufacturing service. 

He has accomplished at least five recombinant proteins form E. coli. and three monoclonal antibodies from CHO or NS0 cells for client’s Phase I/II clinical trial or pre-clinical development purposes. 

He also has experience working with international engineering companies to establish two GMP certified biopharmaceutical facilities for the DCB he served.


Executive Director, Analytical Sciences & QC

Dr. Irene, Ae-Ning Lin, a Ph. D. graduate from University of Maryland, College Park, and Post-doc at University of Wisconsin, Madison, has been working in biotechnology field since 1987. She backed to Taiwan and works in the Process Development Division at Development Center for Biotechnology from 1987-2013. She has over thirty years of experience in purification process development, including therapeutic protein, plasmid DNA, bacterial and viral vaccine, enzyme and antibodies. She also has experience for the set-up and operation/validation of biological CGMP pilot plant for the production of phase I/II mammalian derived biologics. Since 2008 Dr. Lin is the Head of Process R & D Department of CGMP pilot plant in Development Center for Biotechnology as well as the co-project director of protein characterization program for the set-up of LC/MS analytical method for protein structure characterization.

After joined EirGenix from Apr. 1st, 2013, Dr. Lin is responsible for the analytical method development and quality control of biologics in terms of characterization, assay development, assay validation, release specification, stability profile and impurity profile monitoring to ensure the quality of therapeutic biologics.


Senior Director, Clinical Development & Operations

Dr. Barbara Grohmann-Izay has studied medicine, psychology and biostatistics in Vienna, Austria, and expanded her knowledge with attending a postgraduate program of clinical research.

In over 18 years of experience in industrial drug development and academic research, she worked within multiple therapeutic areas like oncology, vaccines (prophylactic and therapeutic), hematology, transplantation, cardio-vascular, inflammatory and metabolic diseases. 

At EirGenix, Dr. Grohmann-Izay is leading the clinical development and operations team, currently working on the broad pipeline of mainly biosimilars at different clinical development stages of which one is close to BLA filing.